About: Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	AB An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone. Recommendations regarding the prevention and management of adverse events, particularly venous thromboembolism and myelosuppression, were provided on the basis of the available evidence and practical experience of panel members. Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma. AB An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone. Recommendations regarding the prevention and management of adverse events, particularly venous thromboembolism and myelosuppression, were provided on the basis of the available evidence and practical experience of panel members. Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma. (en)
Title	Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement (en)
skos:prefLabel	Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement (en)
skos:notation	RIV/65269705:_____/11:#0001362!RIV12-MZ0-65269705
http://linked.open...avai/predkladatel	Fakultní nemocnice Brno
http://linked.open...avai/riv/aktivita	I V
http://linked.open...avai/riv/aktivity	I, V
http://linked.open...iv/cisloPeriodika	5
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Hájek, Roman
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice Brno / (nerozlišená součást)
http://linked.open...dnocenehoVysledku	218805
http://linked.open...ai/riv/idVysledku	RIV/65269705:_____/11:#0001362
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	lenalidomide; multiple myeloma (en)
http://linked.open.../riv/klicoveSlovo	lenalidomide multiple myeloma
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[7F0DFD2D893D]
http://linked.open...i/riv/nazevZdroje	Leukemia
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	16 (xsd:int)
http://linked.open...UplatneniVysledku	2011
http://linked.open...v/svazekPeriodika	25
http://linked.open...iv/tvurceVysledku	Hájek, Roman Dimopoulos, M. A.
http://linked.open...ain/vavai/riv/wos	000290471100002
issn	0887-6924
number of pages	12 (xsd:int)
is http://linked.open...avai/riv/vysledek of	Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software